Researchers have developed DNA aptamers for detecting atropine and timolol maleate in ocular fluid. This breakthrough addresses the limitations of traditional methods for monitoring these low-concentration eye disease treatments, enabling personalized medicine and improving drug delivery efficacy.

Aptamer-modified NK cells (ApEn-NK) are created by chemically anchoring CD30-specific aptamers to the surface of NK cells. These modified cells can specifically target and kill lymphoma cells without reacting with off-target cells. This approach requires no gene editing or cellular damage, offering a novel method for NK cell-targeted immunotherapy.

The 2024 Healthcare+ Expo Taiwan is set to grandly open from December 5th to 8th! The 'Innovative Medical Technology Industry Alliance' pavilion will be located at Booth L218 within the Precision Testing & Great Health Theme Hall on the 4th floor of Nangang Exhibition Center Hall 1. This collaborative exhibit brings together eight leading technology partners, including LABCHINA, GeniCore Biotech, LIS TECH, MEDICARE PRODUCTS, BROADSIMS, Health Saver Medical, and ConcePLT Medic